Abstract
This chapter describes the process of screening that is undertaken once the target for a drug has been identified and the compounds or biologicals have been produced to test against it. Different laboratory assays are used to measure interactions with the target, and depending on the throughput of the screen, may require robotics to automate the process. These technologies along with the relevant terminology used in this particular aspect of drug discovery are described in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ito T et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345–1349
Tran TC et al (2007) Automated quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res 67:11386–11392
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Zanders, E.D. (2011). Screening for Hits. In: The Science and Business of Drug Discovery. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9902-3_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9902-3_9
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-9901-6
Online ISBN: 978-1-4419-9902-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)